Tacere

Benitec Biopharma hit two key milestones recently in its effort to advance its expressed RNAi-based hepatitis C treatment TT-034 into the clinic, securing a commitment to sell A$7 million ($6.7 million) of its stock to new and existing shareholders and receiving a favorable revie

Shares of Benitec Biopharma resumed trading on the Australian Stock Exchange this week after the company announced that it had closed a A$800,000 ($821,760) private placement that it said would give it resources enough to fund a clinical trial of its recently reacquired hepatitis

With Marina Biotech's back against the wall, the RNAi drugs field may soon see the departure of its third player this year, following the bankruptcy of Traversa Therapeutics and the acquisition of Tacere Therapeutics by Benitec Biopharma.

Just six years after a troubled Benitec Biopharma licensed its expressed RNAi hepatitis C drug program to Tacere Therapeutics, a startup founded by former Benitec executives, the two companies have agreed to merge.

Rosetta Genomics announced that it has named Robert Wassman as its new chief medical officer and Dganit Bar as its new chief scientific officer.

Tacere Therapeutics is prepared to file an investigational new drug application for an expressed RNAi treatment for hepatitis C, but is looking to partner the program before doing so after previous collaborator Pfizer pulled back on its in-house RNAi drug efforts, according to Be

For instance, Tacere Therapeutics received $488,958 in two grants, the first of which supports development of a new hepatitis C treatment, as well as a previously undisclosed eye-disease program.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.